Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Monoclonal Antibodies for Inflammatory Bowel Disease Take Center Stage At Digestive Disease Week

This article was originally published in The Pink Sheet Daily

Executive Summary

Studies of Biogen Idec/Elan's Antegren, Abbott's Humira and Protein Design Labs' HuZAF for Crohn's disease were presented at the meeting. Presentations of non-MAb's included Otsuka's OPC-6535, Alizyme's renzapride and Solvay's cilansetron.

You may also be interested in...



Tysabri's Next Steps Include Rheumatoid Arthritis, Crohn's Indications

Elan/Biogen Idec may price the recently approved Tysabri at a premium to other multiple sclerosis therapies in anticipation of the additional indications. The price announcement could come within a few days.

Tysabri's Next Steps Include Rheumatoid Arthritis, Crohn's Indications

Elan/Biogen Idec may price the recently approved Tysabri at a premium to other multiple sclerosis therapies in anticipation of the additional indications. The price announcement could come within a few days.

Antegren BLA Submission For Multiple Sclerosis Could See Approval By Year-End

Biogen Idec and Elan are requesting priority review for the MS submission. Companies are also seeking accelerated approval; BLA is based on one-year data from ongoing AFFIRM and SENTINEL trials.

Related Content

Topics

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel